HIT Screening and Activity Validation
In early drug discovery, Hit (HIT) Screening and Activity Validation is the core link connecting drug targets and lead compounds, directly determining the efficiency of lead discovery and the success rate of subsequent drug development. Accurately screening hit compounds with specific biological activity and validating their binding affinity, action mechanism and in vivo/in vitro activity for therapeutic targets is the premise of developing high-quality innovative drugs. As a professional pharmaceutical CRO with advanced analytical technology platforms, PharmaAnalytica provides comprehensive, technology-driven HIT Screening and Activity Validation services for global pharmaceutical enterprises.
Centered on 13 core analytical and screening technologies including luminescence/fluorescence detection, biophysical interaction analysis, structural biology characterization, high-throughput library screening and in vivo/in vitro functional validation, our service covers the entire process of hit discovery—from high-throughput rapid screening of compound libraries to precise validation of molecular binding affinity, from structural characterization of target-compound complexes to functional activity verification in cellular and animal models. All technologies are independently optimized and validated, with high sensitivity, high specificity and high throughput, fully meeting the technical requirements of early drug discovery for rapid hit mining and accurate activity verification, and providing scientific and reliable data support for the selection and optimization of lead compounds.
Specialized HIT Screening and Activity Validation Services
Luminescence-Based Assays
A high-sensitivity functional screening technology for detecting target biological activity by measuring luminescent signal changes. It leverages luciferase-catalyzed luminescent reactions to quantify enzyme activity, cell signaling pathway activation and cell viability, enabling high-throughput screening of hit compounds for enzyme, receptor and cell-based targets, with the advantages of low background interference, wide linear range and rapid detection, ideal for primary HIT screening.
Fluorescence-Based Assays
A versatile screening and validation technology based on fluorescence signal transduction and detection. It uses fluorescent probes, FRET, FLIPR and other technologies to realize real-time detection of molecular binding, conformational changes, intracellular ion concentration and enzyme activity, with high sensitivity and spatial resolution. It is suitable for both high-throughput primary screening and precise secondary validation of hit compound activity, and can be applied to various target types such as GPCRs, ion channels and kinases.
Surface Plasmon Resonance (SPR)
A label-free biophysical technology for real-time analysis of molecular interaction dynamics. It detects the change of surface plasmon resonance signal caused by target-compound binding to obtain kinetic parameters (kon/koff) and affinity constant (KD), realizing label-free, real-time and quantitative validation of hit compound binding affinity. It is the gold standard for characterizing biomolecular interactions and critical for screening compounds with specific binding activity to therapeutic targets.
Biolayer Interferometry (BLI)
A label-free, high-throughput molecular interaction analysis technology. It measures the interference spectrum change of biological membrane layer caused by molecular binding on the biosensor surface to quantify binding affinity and kinetics, with the advantages of low sample consumption, no need for sample immobilization and high-throughput detection (up to 8 samples in parallel). It is suitable for rapid validation of a large number of hit compounds and high-throughput screening of compound libraries for weak-binding hit mining.
Isothermal Titration Calorimetry (ITC)
A label-free technology for quantitative analysis of the thermodynamics of molecular interactions. It measures the heat change generated during the titration of hit compounds with targets to obtain complete thermodynamic parameters (ΔH, ΔS, ΔG, KD), revealing the binding mechanism of compounds at the energy level and distinguishing specific binding from non-specific binding. It is the core technology for in-depth validation of hit compound binding specificity and affinity, and provides a theoretical basis for compound structural optimization.
Single-Crystal X-ray Diffraction (SCXRD)
The gold standard for high-resolution characterization of the three-dimensional structure of target-hit compound complexes. It analyzes the crystal diffraction pattern to obtain atomic-level structural information of the complex, clarifying the binding mode, interaction sites and spatial conformation of the compound with the target active pocket. It is critical for verifying the binding mechanism of hit compounds and providing structural guidance for the rational design and optimization of lead compounds, and the data can support IND application intellectual property protection.
Microcrystal Electron Diffraction (MicroED)
A revolutionary structural biology technology for crystal structure analysis of micro/nano-scale crystals. It uses transmission electron microscopy to collect diffraction data of microcrystals (nm-μm level) that cannot be characterized by SCXRD, realizing rapid structural determination of target-hit compound complexes with only a small amount of sample (mg level), and can complete high-precision structure analysis in one day. It is especially suitable for hit compounds that are difficult to cultivate large single crystals and rapid structural validation of a large number of hit compounds.
DNA-Encoded Library Screening
A high-throughput compound library screening technology for mining hit compounds from massive chemical space. It links each small molecule compound with a unique DNA sequence for coding, and can screen millions to billions of compounds in a single experiment. After incubation with the target, the bound compound-DNA conjugates are enriched and sequenced to identify hit compounds, with the advantages of ultra-high throughput, low sample consumption and wide chemical diversity. It is the core technology for exploring novel hit compounds and discovering new drug targets.
Zebrafish Screening
An in vivo functional screening technology based on the zebrafish animal model. Zebrafish has high homology with human genes (82% of disease-related genes are conserved), transparent embryos and high reproductive capacity, enabling in vivo high-throughput screening of hit compounds for developmental biology, anti-tumor, anti-inflammatory and neuroprotective targets. It can realize real-time observation of compound in vivo activity and toxicity, and is an important bridge between in vitro screening and mammalian animal validation.
Organoid-Based Screening
A three-dimensional cell model screening technology that simulates the structure and function of human tissues/organs. It uses stem cell-derived organoids (e.g., liver, intestine, tumor, brain organoids) to screen hit compounds, which can more realistically simulate the in vivo microenvironment of human tissues and the action mode of drugs compared with traditional 2D cell models. It is suitable for validating the in vitro functional activity and tissue specificity of hit compounds, and predicting the in vivo efficacy and toxicity of compounds at an early stage.
High-Throughput Screening (HTS)
A core technology for large-scale rapid screening of hit compounds from compound libraries. It integrates automated liquid handling, high-throughput detection and data analysis systems, and can complete the screening of 10^4-10^6 compounds in a short time by matching luminescence/fluorescence and other detection technologies. It is customized for different target types (enzyme, receptor, cell-based) to establish high-throughput screening models, realizing rapid and efficient mining of hit compounds with potential biological activity from massive compound libraries.
Affinity Selection-Mass Spectrometry (AS-MS)
A technology combining affinity enrichment and mass spectrometry for label-free screening and identification of hit compounds. It uses the target as the affinity probe to enrich hit compounds that specifically bind to the target from complex compound libraries or biological samples, and then identifies the structure and quantifies the affinity of the enriched compounds by mass spectrometry. It has the advantages of no need for fluorescent/luminescent labeling, wide applicability and ability to screen unmodified compounds, and is suitable for mining novel hit compounds for difficult-to-screen targets.
Nuclear Magnetic Resonance (NMR) Spectroscopy
A multi-functional technology for hit screening and binding mechanism validation based on nuclear magnetic resonance signal analysis. It can realize label-free screening of hit compounds from compound libraries by using 1D/2D NMR technologies (e.g., WaterLOGSY, STD), and characterize the binding sites and spatial conformation of hit compounds with target active pockets at the atomic level, realizing the integration of hit screening and structural validation. It is especially suitable for screening hit compounds for macromolecular targets such as proteins and nucleic acids, and mining weak-binding fragment hits for fragment-based drug discovery.
Why Choose PharmaAnalytica?
Full Technology Ecosystem
13 core technologies cover all links of HIT screening and activity validation, from in vitro high-throughput rapid screening to in-depth biophysical/structural validation, and from in vitro cell model to in vivo animal/organoid functional verification, realizing one-stop hit discovery.
Customized Targeted Solutions
According to the characteristics of different therapeutic targets (enzyme, receptor, ion channel, nucleic acid, cell-based), customized screening and validation protocols are established, and technical support for difficult-to-screen targets (membrane proteins, protein-protein interactions) is provided.
Regulatory-Compliant Data Management
All experimental data is collected and managed in accordance with GLP guidelines, with complete audit trails and data traceability, and the generated reports can support the subsequent preclinical research and drug registration application of lead compounds.
Expert Cross-Disciplinary Team
Our team consists of analytical chemists, structural biologists, cell biologists and drug discovery experts, who provide in-depth data interpretation and professional suggestions for compound structural optimization and lead selection, and help enterprises accelerate the drug discovery process.
PharmaAnalytica takes advanced analytical and screening technologies as the core, and is committed to providing efficient, accurate and comprehensive HIT Screening and Activity Validation services for pharmaceutical enterprises. We help you mine high-quality hit compounds from massive chemical space, accurately validate their biological activity and binding mechanism, and lay a solid technical foundation for the subsequent optimization of lead compounds and the development of innovative drugs, accelerating the transformation of drug discovery from target to clinical candidate drugs.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
